The US Food and Drug Administration has approved a new drug for the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
After reviewing data from 2 randomized placebo-controlled Phase 3 trials and an open-label extension, the FDA has approved a new option for the treatment of adults with chronic immune thrombocytopenia.
...
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
